Supporting Education & Research ​

We focus to continuously develop new specialties, new treatments, and invest in medical innovations that bring a brighter future. In addition to this, we are constantly committed to activities and initiatives within disease communities which support awareness and better research in areas of need, particularly within rare diseases.

Arrigo Prize: Committed to excellence in research

Established in 2000 in memory of Arrigo Recordati, this international recognition aims to promote scientific research. The prize awards €100,000 to a scientist who has particularly stood out for formulating an innovative research project. The winner is selected by an independent panel formed of global experts.

The 2022 edition, open to young researchers from anywhere in the world, was dedicated to the promotion and recognition of excellence in research on pituitary disorders. The prize was awarded to Dr Sabrina Chiloiro for her project on the role of the immune microenvironment in growth hormone (GH) secreting pituitary tumours. The award ceremony took place in Milan on 23 May 2022 during the European Congress of Endocrinology.

The 2024 edition is currently open, with pre-selection application period from June 1st – October 31st 2023, and is dedicated to the promotion and recognition of excellence in research within paediatric oncology, specifically neuroblastoma. 

Shining a light on the burden of a rare disease like
Cushing’s syndrome

This is Cushing is an award-winning* global awareness campaign which aims to spread education on Cushing’s Syndrome. The campaign was designed together with the award-winning photographer Stefano Schirato and Federico II University of Naples Full Professors of Endocrinology Annamaria Colao and Rosario Pivonello to capture a moment in time of someone living with Cushing’s Syndrome.


Cushing’s Syndrome is a rare endocrine disorder caused by a chronic exposure to excessive levels of cortisol affecting less than 1 in 10,000 people in the European Union, which is equivalent to fewer than 51,000 patients. The disease is associated with significant morbidity and mortality due to cardiovascular and metabolic complications. In addition to the physical features, psychiatric manifestations are also a significant part of the disease which drastically affect patients’ quality of life.


*Winner of the 2023 PMEA Award for Patient Centricity. Read more.

Filling the educational gap in rare diseases

  • Recordati Rare Diseases Foundation aims to organise training on rare diseases to improve diagnosis and spread currently available knowledge on therapeutic options.

  • The organisation promotes scientific sharing of experience and knowledge between centre of expertise and specialists across the globe.

  • Every year, the Foundation proposes tailored face to face courses that aim to provide physicians, worldwide, with clinically useful and the most up-to-date information concerning current knowledge and recommendations for care.

  • The Foundation has delivered over 70 courses to over 3000 healthcare professionals since its creation.


The personal data that you provide by compiling this form will be used by Recordati Industria Chimica e Farmaceutica S.p.A. (“Recordati”) – the “Data Controller” – solely for performing activities connected with the provision of the email alert service and it will be processed manually, by computer and via the internet in a manner that will guarantee its security and confidentiality. It is not compulsory for you to give your data, however, if you refuse to allow it to be processed, then it will be impossible for Recordati to provide you with the above-mentioned service. Your personal data may be passed on to other companies that belong to the RECORDATI Group or to associate companies of the Group and to third parties that Recordati uses to provide the service to you.


In any event we assure you that your data will be processed solely for the above purposes and using the above methods.


The company Tech Style S.r.l. has been appointed as external Data Processor in accordance with Art. 29 of the Privacy Code, because it has been engaged to maintain the technological part of the website. The Director of Investor Relations and Corporate Communication of Recordati S.p.a. has been appointed as internal Data Processor of Recordati in accordance with article 29 of the Privacy Code.


A data subject shall have the right to obtain at any moment confirmation of whether or not data is held on him/her, to know its content and origin, to check its accuracy or to ask for it to be added to, updated or rectified (article 7 of the Privacy Code).


Requests must be sent to the Data Processor of Recordati:
   by email, to the address: ;
   or by ordinary mail to Recordati Industria Chimica e Farmaceutica S.p.A. – Director of Investor Relations and Corporate Communications – 1 Via Civitali – 20148 Milan.


In accordance with article 23 of Legislative Decree No. 196/03 on personal data protection, having read the above information, I hereby authorise Recordati S.p.A. to process my personal data for the purposes set out in that same information. I am aware that if I refuse, Recordati will not be able to enable its email alert service for me.


Subsequent withdrawal of consent to the data processing mentioned in the preceding paragraph will result in the cancellation of the subscription request or cancellation of the subscription to the email alert service.